Inhibrx Biosciences (INBX) Accumulated Expenses (2023 - 2026)

Inhibrx Biosciences (INBX) has reported Accumulated Expenses for 3 consecutive years, with $25.5 million the latest figure, recorded in Q4 2025.

• In Q4 2025, Accumulated Expenses fell 14.59% year-over-year to $25.5 million; the TTM figure through Dec 2025 stood at $25.5 million (down 14.59% YoY), while the FY2025 annual figure was $25.5 million, down 14.59% from the prior year.
• Accumulated Expenses fell to $25.5 million in Q4 2025 per INBX's latest filing, from $27.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $43.3 million in Q4 2023 and bottomed at $23.9 million in Q2 2024.
• Historically, Accumulated Expenses has averaged $30.1 million across 3 years, with a median of $29.2 million in 2024.
• Annual changes were most pronounced in 2024 — Accumulated Expenses tumbled 30.96% — and 2025, when it increased 19.35%.
• Inhibrx Biosciences' Accumulated Expenses stood at $43.3 million in 2023, then sank by 30.96% to $29.9 million in 2024, then decreased by 14.59% to $25.5 million in 2025.
• Business Quant data shows INBX's Accumulated Expenses at $25.5 million in Q4 2025, $27.0 million in Q3 2025, and $28.5 million in Q2 2025.